Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21525869rdf:typepubmed:Citationlld:pubmed
pubmed-article:21525869lifeskim:mentionsumls-concept:C0006147lld:lifeskim
pubmed-article:21525869lifeskim:mentionsumls-concept:C0032659lld:lifeskim
pubmed-article:21525869lifeskim:mentionsumls-concept:C0021270lld:lifeskim
pubmed-article:21525869lifeskim:mentionsumls-concept:C0016365lld:lifeskim
pubmed-article:21525869lifeskim:mentionsumls-concept:C0332157lld:lifeskim
pubmed-article:21525869lifeskim:mentionsumls-concept:C0743284lld:lifeskim
pubmed-article:21525869lifeskim:mentionsumls-concept:C0681842lld:lifeskim
pubmed-article:21525869lifeskim:mentionsumls-concept:C0679083lld:lifeskim
pubmed-article:21525869lifeskim:mentionsumls-concept:C0870071lld:lifeskim
pubmed-article:21525869pubmed:issue6lld:pubmed
pubmed-article:21525869pubmed:dateCreated2011-5-19lld:pubmed
pubmed-article:21525869pubmed:abstractTextThe likelihood of significant exposure to drugs in infants through breast milk is poorly defined, given the difficulties of conducting pharmacokinetics (PK) studies. Using fluoxetine (FX) as an example, we conducted a proof-of-principle study applying population PK (popPK) modeling and simulation to estimate drug exposure in infants through breast milk. We simulated data for 1,000 mother-infant pairs, assuming conservatively that the FX clearance in an infant is 20% of the allometrically adjusted value in adults. The model-generated estimate of the milk-to-plasma ratio for FX (mean: 0.59) was consistent with those reported in other studies. The median infant-to-mother ratio of FX steady-state plasma concentrations predicted by the simulation was 8.5%. Although the disposition of the active metabolite, norfluoxetine, could not be modeled, popPK-informed simulation may be valid for other drugs, particularly those without active metabolites, thereby providing a practical alternative to conventional PK studies for exposure risk assessment in this population.lld:pubmed
pubmed-article:21525869pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21525869pubmed:languageenglld:pubmed
pubmed-article:21525869pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21525869pubmed:citationSubsetAIMlld:pubmed
pubmed-article:21525869pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21525869pubmed:statusMEDLINElld:pubmed
pubmed-article:21525869pubmed:monthJunlld:pubmed
pubmed-article:21525869pubmed:issn1532-6535lld:pubmed
pubmed-article:21525869pubmed:authorpubmed-author:IlettK FKFlld:pubmed
pubmed-article:21525869pubmed:authorpubmed-author:ItoSSlld:pubmed
pubmed-article:21525869pubmed:authorpubmed-author:PanchaudAAlld:pubmed
pubmed-article:21525869pubmed:authorpubmed-author:BeggE JEJlld:pubmed
pubmed-article:21525869pubmed:authorpubmed-author:TaddioAAlld:pubmed
pubmed-article:21525869pubmed:authorpubmed-author:KristensenJ...lld:pubmed
pubmed-article:21525869pubmed:authorpubmed-author:CsajkaCClld:pubmed
pubmed-article:21525869pubmed:authorpubmed-author:Garcia-Bourni...lld:pubmed
pubmed-article:21525869pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21525869pubmed:volume89lld:pubmed
pubmed-article:21525869pubmed:ownerNLMlld:pubmed
pubmed-article:21525869pubmed:authorsCompleteYlld:pubmed
pubmed-article:21525869pubmed:pagination830-6lld:pubmed
pubmed-article:21525869pubmed:meshHeadingpubmed-meshheading:21525869...lld:pubmed
pubmed-article:21525869pubmed:meshHeadingpubmed-meshheading:21525869...lld:pubmed
pubmed-article:21525869pubmed:meshHeadingpubmed-meshheading:21525869...lld:pubmed
pubmed-article:21525869pubmed:meshHeadingpubmed-meshheading:21525869...lld:pubmed
pubmed-article:21525869pubmed:meshHeadingpubmed-meshheading:21525869...lld:pubmed
pubmed-article:21525869pubmed:meshHeadingpubmed-meshheading:21525869...lld:pubmed
pubmed-article:21525869pubmed:meshHeadingpubmed-meshheading:21525869...lld:pubmed
pubmed-article:21525869pubmed:meshHeadingpubmed-meshheading:21525869...lld:pubmed
pubmed-article:21525869pubmed:meshHeadingpubmed-meshheading:21525869...lld:pubmed
pubmed-article:21525869pubmed:meshHeadingpubmed-meshheading:21525869...lld:pubmed
pubmed-article:21525869pubmed:meshHeadingpubmed-meshheading:21525869...lld:pubmed
pubmed-article:21525869pubmed:meshHeadingpubmed-meshheading:21525869...lld:pubmed
pubmed-article:21525869pubmed:meshHeadingpubmed-meshheading:21525869...lld:pubmed
pubmed-article:21525869pubmed:meshHeadingpubmed-meshheading:21525869...lld:pubmed
pubmed-article:21525869pubmed:year2011lld:pubmed
pubmed-article:21525869pubmed:articleTitlePrediction of infant drug exposure through breastfeeding: population PK modeling and simulation of fluoxetine exposure.lld:pubmed
pubmed-article:21525869pubmed:affiliationDivision of Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, Ontario, Canada.lld:pubmed
pubmed-article:21525869pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21525869pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:21525869pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed